by Truveta staff | Jan 23, 2024 | Research
Overall prescribing rates (GLP-1 RA prescriptions per total prescriptions) have remained stable in the last 3 months, with rates in December 2023 about the same as rates in November 2023 and October 2023. For the anti-diabetic medications (ADMs), the number of...
by Truveta staff | Dec 15, 2023 | Research
As 2023 draws to a close and we reflect on a busy and exciting year for Truveta, something that stands out is the breadth and depth of research Truveta Research has been able to produce using Truveta Data and Truveta Studio. From studying new Alzheimer’s disease...
by Truveta Research | Nov 27, 2023 | Research, Research Insights
Today Truveta announced new comparative effectiveness research exploring weight loss among patients taking semaglutide (Ozempic) and tirzepatide (Mounjaro). Glucagon-like peptide 1 receptor agonist-based (GLP-1 RA) medications, including semaglutide and the dual GLP-1...
by Truveta staff | Nov 21, 2023 | Data
ISPOR Europe 2023 provided Truveta an opportunity to showcase research findings, interact with life sciences leaders from across the globe, and gain insight into how different audiences view current challenges and opportunities related to real-world data (RWD). Here...
